Skip to content

Launched · SEC filings

T. Rowe Price Biotech ETF

TDNANasdaqWe have not yet analyzed this fund's documents to determine what it sets out to do. This is typical for new listings awaiting their first analysis pass.

$23.07−0.80 (−3.36%)

At close: Oct 13, 2026, 4:00 PM

Intraday session: down, 15 prints from 23.88 to 23.07. Range 23.07 to 23.65. Use the arrow keys to read each point.23.2023.4023.6010 AM12 PM2 PM4 PM
Expense ratio
0.55%
Fund size
$10M
1Y total return
—
Yield · Last 12 months
—
Holdings
87
Avg volume · 30D
0M sh
NAV per share
$24.20
52W range
low $23.01high $25.68
Launched
Filings
SEC EDGAR

The ETF.net TDNA Grade

—

Mandate not yet analyzed

We have not yet analyzed this fund's documents to determine what it sets out to do. This is typical for new listings awaiting their first analysis pass.

TDNA Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
87
Top-10 weight
28%
Largest holding
ARGX4.8%

Geography

  • United States90.34%
  • Netherlands4.89%
  • Ireland1.62%
  • United Kingdom1.44%
  • Denmark0.77%
  • Canada0.64%
  • France0.30%
The fund’s holdings, weight-ordered — page 1 of 6.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001ARGXArgenx SE Adr Adr4.83%567$468K70
002KYMRKymera Therapeutics Inc Common Stock USD.00014.21%3,629$408K111
003KODKodiak Sciences Inc Common Stock USD.00012.93%2,836$283K64
004PCVXVaxcyte Inc Common Stock USD.0012.48%3,359$240K109
005NTRANatera Inc Common Stock2.43%586$235K238
006INSMInsmed Inc Common Stock USD.012.37%2,281$229K192
007UTHRUnited Therapeutics Corp Common Stock USD.012.31%407$224K266
008MRNAModerna Inc Common Stock USD.00012.31%992$223K286
009VRTXVertex Pharmaceuticals Inc Common Stock USD.012.28%433$221K422
010RVMDRevolution Medicines Inc Common Stock2.28%1,161$220K176
011ALNYAlnylam Pharmaceuticals Inc Common Stock USD.011.93%804$187K259
012BBIOBridgebio Pharma Inc Common Stock1.86%2,760$180K119
013DNTHDianthus Therapeutics Inc Common Stock USD.0011.86%2,182$180K84
014CYTKCytokinetics Inc Common Stock USD.0011.81%2,789$175K134
015RYTMRhythm Pharmaceuticals Inc Common Stock1.79%1,911$173K82

Showing 1–15 of 87 holdings

TDNA Performance

Launched Sep 16, 2026

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.
TDNA$9,645
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$10,042
Oct 5, 2026 to Oct 12, 2026. TDNA $9,645. SPY $10,042. Use the arrow keys to read each point.$9,477$9,787$10,098Oct 5Oct 8Oct 12

Oct 5, 2026 – Oct 12, 2026

Returns run to the last market close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for TDNA. Periods over one year show the average yearly return.
PeriodTDNA
Year to dateFund launched this year—
1 monthFund is under 1 month old—
3 monthsFund is under 3 months old—
1 yearFund is under 1 year old—
3 yearsFund is under 3 years oldper year—
5 yearsFund is under 5 years oldper year—
10 yearsFund is under 10 years oldper year—

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for TDNA
YearReturn barTDNA
2026 YTD−6.3%

History from Sep 17, 2026

TDNA in the news

Filtered to TDNA · T. Rowe

TDNA Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
—Last 12 months
Payout per share
—Last 12 months

Listed Sep 2026. No distributions yet.

TDNA Risk

How much the fund’s monthly returns vary, scaled to a year.
—
Launched Sep 2026; fills in after 12 months
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
Launched Sep 2026; fills in after 12 months
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
Launched Sep 2026; fills in after 12 months
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.00
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

TDNA Cost

Expense ratio0.55%

TDNA costs $55.00 a year on $10,000.